Results 141 to 150 of about 4,367 (184)

Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions. [PDF]

J Pers Med
Pool IA, Otten AT, Kosterink JGW, Dijkstra G, Mian P, Bourgonje AR.   +5 more
europepmc   +1 more source

How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review. [PDF]

Cureus
Abu Osba Y, Elshebli S, Abureesh A, Al-Shraideh A, Yousef Y, Abu-Shaban M, Abureesh O.   +6 more
europepmc   +1 more source

Risankizumab for psoriasis

, 2020
openaire   +1 more source

The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy. [PDF]

Med Sci (Basel)
Lemiesz P, Nowowiejska-Purpurowicz J, Kaminski TW, Flisiak I.   +3 more
europepmc   +1 more source

Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania. [PDF]

Medicina (Kaunas)
Indrisiunaite E, Jonaityte IR, Karmaziene T, Raudonis T.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Risankizumab

Reactions Weekly
  +19 more sources

Risankizumab for the treatment of psoriasis

Expert Review of Clinical Pharmacology, 2019
Introduction: The interleukin （IL）-23 and IL-17 pathway is closely related to the pathogenesis of psoriasis. This pathway is considered to be an important target for treating psoriasis. Risankizumab can selectively inhibit IL-23p19 subunit and for the treatment of psoriasis. This article aims to review risankizumab and provides reference for clinicians.
Junyi Yang
exaly   +3 more sources